Hugel posts record Q1 earnings with balanced product growth, global momentum

Hugel, a Korean medical aesthetics specialist, said it achieved record-high first-quarter earnings for 2025, driven by strong performances across all business segments and growing international sales.

According to its consolidated financial statement released Thursday, Hugel reported sales of 89.8 billion won ($63.8 million), operating profit of 39 billion won, and net profit of 30.9 billion won in the first quarter. Compared to the same period last year, these figures represent increases of 20.9 percent, 62.6 percent, and 35.9 percent, respectively.

The strong earnings were fueled by balanced growth across Hugel’s core product portfolio, including botulinum toxin, hyaluronic acid (HA) fillers, and cosmetics.

Sales of Hugel’s flagship botulinum toxin product, Botulax, reached 40.7 billion won, accounting for 45 percent of total revenue. This represents an 18.8 percent increase from the same period last year. Regionally, the Asia-Pacific market—including China, Australia, and Taiwan—led growth with a 54 percent increase.

The company’s HA filler line, which includes The Chaeum and the Byryzn Skinbooster, posted sales of 34.4 billion won, up 17.7 percent from the previous year. Robust sales were reported not only in Korea but also across Asia-Pacific, North and South America, and Europe.

Hugel’s cosmetics division also delivered a notable performance, with revenue rising 39.3 percent to 13.2 billion won. Its dermocosmetic brand Wellage and high-end brand Byryzn BR have expanded consumer reach through successive new product launches and diversified Korean and overseas distribution channels.

"A coordinated company-wide effort enabled all of Hugel’s product categories to achieve solid results in both domestic and global markets, culminating in another record-breaking first quarter," a Hugel spokesperson said. "Looking ahead, we will leverage upcoming milestones such as U.S. shipments and Middle East market entries to strengthen our global presence."

In a separate announcement, Hugel’s board of directors approved the cancellation of 300,000 treasury shares, scheduled for May 15. The move reflects the company’s continued commitment to shareholder returns.